TheEdgeResearch
Home / Stocks / WHWK

Whitehawk Therapeutics Inc (WHWK)

NASDAQ Healthcare Biotechnology
$3.74 ▼ -3.11%
Market Cap
$213.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.81
52-Wk Range
1.82-5.5
CEO
David J. Lennon
Country
US
Currency
USD

Whitehawk Therapeutics Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Morristown, NJ, US. The stock last traded at $3.74, down 3.11% on the session, giving a market capitalisation of $213.2M. On trailing twelve-month figures it carries a trailing P/E of -3.34, a net margin of 0.0%. Its beta of 0.81 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.34
Price / Sales
0.00
Price / Book
1.69
EV / EBITDA
-1.57
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
17.38
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
32
IPO date
2017-08-01
Headquarters
Morristown, NJ, US
About Whitehawk Therapeutics Inc

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Comparable companies

Whitehawk Therapeutics Inc is most often compared with the following Healthcare names:

ATOSCLNNCNTXIMMXMGNXONCYOVIDPLRXTVGNZNTL
More research on WHWK
WHWK technical analysis WHWK TheEdge Score Compare against peers
Open full interactive analysis & DCF →